tradingkey.logo
tradingkey.logo
Suchen

AxoGen Inc

AXGN
Zur Watchlist hinzufügen
44.020USD
-2.170-4.70%
Handelsschluss 07/01, 16:00ETKurse um 15 Minuten verzögert
2.34BMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über AxoGen Inc Unternehmen

Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating.

AxoGen Inc Informationen

BörsenkürzelAXGN
Name des UnternehmensAxoGen Inc
IPO-datumDec 17, 1986
CEODale (Michael Donald)
Anzahl der mitarbeiter451
WertpapierartOrdinary Share
GeschäftsjahresendeDec 17
Addresse13631 Progress Blvd.
StadtALACHUA
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl32615
Telefon13864626817
Websitehttps://www.axogeninc.com/
BörsenkürzelAXGN
IPO-datumDec 17, 1986
CEODale (Michael Donald)

Führungskräfte von AxoGen Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Lindsey Hartley
Ms. Lindsey Hartley
Chief Financial Officer
Chief Financial Officer
65.15K
+6.77%
Mr. Jens Schroeder Kemp
Mr. Jens Schroeder Kemp
Chief Marketing Officer
Chief Marketing Officer
64.95K
-6.16%
Mr. Paul G. Thomas
Mr. Paul G. Thomas
Independent Chairman of the Board
Independent Chairman of the Board
28.93K
+65.23%
Mr. Erick Wayne Devinney
Mr. Erick Wayne Devinney
Chief Innovation Officer
Chief Innovation Officer
--
--
Ms. Amy A. Mcbride-Wendell
Ms. Amy A. Mcbride-Wendell
Lead Independent Director
Lead Independent Director
--
--
Mr. Alan M. Levine
Mr. Alan M. Levine
Independent Director
Independent Director
--
--
Mr. John H. Johnson
Mr. John H. Johnson
Independent Director
Independent Director
--
--
Mr. William P. (Bill) Burke
Mr. William P. (Bill) Burke
Independent Director
Independent Director
--
--
Dr. Joseph (Adrian) Tyndall, M.D.
Dr. Joseph (Adrian) Tyndall, M.D.
Independent Director
Independent Director
--
--
Mr. Marc A. Began
Mr. Marc A. Began
Executive Vice President, Chief Compliance Officer, General Counsel
Executive Vice President, Chief Compliance Officer, General Counsel
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Lindsey Hartley
Ms. Lindsey Hartley
Chief Financial Officer
Chief Financial Officer
65.15K
+6.77%
Mr. Jens Schroeder Kemp
Mr. Jens Schroeder Kemp
Chief Marketing Officer
Chief Marketing Officer
64.95K
-6.16%
Mr. Paul G. Thomas
Mr. Paul G. Thomas
Independent Chairman of the Board
Independent Chairman of the Board
28.93K
+65.23%
Mr. Erick Wayne Devinney
Mr. Erick Wayne Devinney
Chief Innovation Officer
Chief Innovation Officer
--
--
Ms. Amy A. Mcbride-Wendell
Ms. Amy A. Mcbride-Wendell
Lead Independent Director
Lead Independent Director
--
--
Mr. Alan M. Levine
Mr. Alan M. Levine
Independent Director
Independent Director
--
--

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von AxoGen Inc?

Die fünf größten Anteilseigner von AxoGen Inc sind: Ms. Lindsey Hartley

Wie viele Institutionen halten Anteile an AxoGen Inc (AXGN)?

Mit Stand vom 2026Q1 halten 399 Institutionen Anteile an AxoGen Inc, mit einem Gesamtmarktwert von etwa 48.71M, was 91.60% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 3148593.00 gestiegen.